BeiGene (BGNE)
(Delayed Data from NSDQ)
$201.99 USD
+3.40 (1.71%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $202.05 +0.06 (0.03%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$201.99 USD
+3.40 (1.71%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $202.05 +0.06 (0.03%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum D VGM
Zacks News
Is a Surprise Coming for BeiGene (BGNE) This Earnings Season?
by Zacks Equity Research
BeiGene (BGNE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Down -14.15% in 4 Weeks, Here's Why BeiGene, Ltd. (BGNE) Looks Ripe for a Turnaround
by Zacks Equity Research
BeiGene, Ltd. (BGNE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Anika (ANIK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Anika Therapeutics' (ANIK) Q4 earnings call, investors are likely to focus on the sales performance of its Osteoarthritis Pain (OAP) Management, Joint Preservation and Restoration segments.
Entera Bio (ENTX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
In the absence of a marketed product, Entera Bio (ENTX) is expected to provide an update on its pipeline candidates, mainly EB613 and EB612, for the treatment of osteoporosis and hypoparathyroidism, respectively.
Will Top-Line Contraction Affect Altice (ATUS) Q4 Earnings?
by Zacks Equity Research
Altice's (ATUS) top line is likely to decline year over year. Macroeconomic uncertainty, stiff competition, rising programming costs per consumer, and a hefty financial burden likely limit its earning potential.
Will Higher Revenues Benefit Keysight (KEYS) Q1 Earnings?
by Zacks Equity Research
Keysight's (KEYS) top-line performance in the first quarter of fiscal 2023 is likely to benefit from solid demand for its electronic design and test solutions and a robust 5G portfolio.
Is Apexigen, Inc. (APGN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Apexigen, Inc. (APGN) and BeiGene, Ltd. (BGNE) have performed compared to their sector so far this year.
Will Top-Line Expansion Aid Cambium (CMBM) Q4 Earnings?
by Zacks Equity Research
Cambium's (CMBM) ongoing innovation efforts, combined with a strong portfolio of fixed wireless broadband and Wi-Fi networking solutions likely to have a positive impact on company's fourth-quarter earnings.
Can Zymeworks (ZYME) Beat Expectations This Earnings Season?
by Zacks Equity Research
In the absence of a marketed product, Zymeworks (ZYME) is expected to provide an update on its pipeline candidates, mainly zanidatamab for the treatment of patients with HER2-expressing cancers, at the fourth-quarter conference call.
Will Lower Patient Days Hurt Community Health (CYH) Q4 Earnings?
by Zacks Equity Research
Community Health's (CYH) fourth-quarter results are likely to reflect growth in adjusted admissions and operating expenses.
Jazz (JAZZ) Gastric Cancer Study Shows Improved Overall Survival
by Zacks Equity Research
Jazz (JAZZ) reports data from a mid-stage study on its investigational bispecific antibody targeting HER2-expressing mGEA. The treatment achieved an overall survival rate of 84% in 18 months.
What Makes BeiGene, Ltd. (BGNE) a Good Fit for 'Trend Investing'
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, BeiGene, Ltd. (BGNE) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Zymeworks (ZYME) Up After Jazz Exercises Option for Cancer Drug
by Zacks Equity Research
Following positive data from a mid-stage study evaluating Zymeworks' (ZYME) lead candidate, Jazz (JAZZ) exercises its option to acquire the rights to develop and market this candidate.
Zymeworks (ZYME) Up on Licensing Deal With Jazz Pharmaceuticals
by Zacks Equity Research
Zymeworks (ZYME) inks a deal to license its lead candidate, zanidatamab, to Jazz Pharmaceuticals for the development and commercialization of the candidate in all territories except Asia-Pacific.
BeiGene, Ltd. (BGNE) Soars 20.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
BeiGene, Ltd. (BGNE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Why BeiGene (BGNE) Might Surprise This Earnings Season
by Zacks Equity Research
BeiGene (BGNE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in the Cards for Sesen Bio's (SESN) Q2 Earnings?
by Zacks Equity Research
Sesen Bio's (SESN) Q2 performance is likely to reflect cost savings from the company's restructuring plans as the company continues to seek a potential partner for the further development of Vicineum.
Novartis (NVS) Announces Positive Data on Oncology Drug
by Zacks Equity Research
Novartis' (NVS) anti-PD-1 monoclonal antibody, tislelizumab, significantly extends median overall survival in first-line advanced esophageal cancer combined with chemotherapy.
Biotech Stock Roundup: MRNA's Jab Update, ACER Down on Regulatory News & More
by Zacks Equity Research
Regulatory and other updates from Moderna (MRNA) and Acer (ACER) are a few key highlights from the biotech sector during the past week.
BeiGene, Ltd. (BGNE) Soars 15.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
BeiGene, Ltd. (BGNE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
AbCellera Biologics Inc. (ABCL) Stock Jumps 9.3%: Will It Continue to Soar?
by Zacks Equity Research
AbCellera Biologics Inc. (ABCL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Amarin (AMRN) Q1 Earnings & Sales Hurt by Vascepa Generics
by Zacks Equity Research
Amarin's (AMRN) Vascepa sales decline year over year amid rising generic competition and COVID-related disruptions during the first quarter. The company's stock falls significantly on May 4.
Why Earnings Season Could Be Great for BeiGene (BGNE)
by Zacks Equity Research
BeiGene (BGNE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
5 Large-Cap Stocks to Buy Ahead of Q1 Earnings This Week
by Nalak Das
Five large-cap companies with a favorable Zacks Rank will report first-quarter earnings results this week. These are: CI, HST, BGNE, VRTX and EOG.
BeiGene (BGNE) Brukinsa Superior to Imbruvica in Leukemia Study
by Zacks Equity Research
BeiGene (BGNE) is comparing Brukinsa to AbbVie's Imbruvica as a treatment for R/R CLL or SLL. Brukinsa achieves superior ORR versus Imbruvica in a phase III study.